Monet Pharmaceuticals

Monet Pharmaceuticals is a private U.S. biotech company focused on early-stage drug discovery using its licensed Protein Painting technology. The company was formed to commercialize structural biology methods that identify druggable interaction hot spots within protein-protein interfaces, with the goal of enabling faster discovery of novel therapeutics. Publicly available information indicates a particular interest in immune checkpoint biology, including PD-1/PD-L1, for oncology applications such as lung cancer and brain metastases. Monet appears to be a platform-oriented discovery company rather than a late-stage clinical developer, and no marketed products or clinical-stage assets were identified in public sources.